Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

about

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

P2860

Q49539698-F98F558D-F45F-455C-AD4B-D264AC991E6D Q52560420-9F7425D8-E869-4264-B9B9-EAE42F3226FC Q55281964-EDCE13F5-382C-453D-9768-A7A0F6EFE3A8

P2860

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38763837

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

@en

type

Item

label

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

@en

prefLabel

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

@en

P1476

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

@en

P2093

Andrea Ferrario

http://www.w3.org/2001/XMLSchema#string

Claudia Basilico

http://www.w3.org/2001/XMLSchema#string

Francesco Passamonti

http://www.w3.org/2001/XMLSchema#string

Margherita Maffioli

http://www.w3.org/2001/XMLSchema#string

P2860

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report.

High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.

P304

367-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1288213

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Merli

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28140696

http://www.w3.org/2001/XMLSchema#string

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

about

P2860

P2860

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698